twenty-six patients affected by acute leukemia were treated with 4-demethoxydaunorubicin ( idarubicin ) , a new anthracycline compound which in experimental leukemias showed an antitumoral activity superior to daunorubicin ( dnr ) and doxorubicin ( dx ) , with a higher ratio of active to cardiotoxic doses .
C0011015
daunorubicin
C0013089
doxorubicin